Please login to the form below

Not currently logged in
Email:
Password:

Merck appoints ex-Pfizer exec as global head of oncology

Maya Martinez-Davis succeeds Andrew Schiermeier in the role

Merck Maya Martinez-DavisDarmstadt, Germany-based Merck has appointed Maya Martinez-Davis as the new global head of its oncology franchise.

Reporting to Merck's Rehan Verjee, chief marketing and strategy officer of its healthcare business, Martinez-Davis will be based out of the firm's Massachusetts office.

In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell lung cancer therapy, which is expected in 2017.

Prior to joining Merck, Martinez-Davis had spent over a decade at Pfizer, occupying increasingly senior executive roles, most recently of which was as North America regional president, oncology.

Verjee said: “Maya's considerable experience in oncology, which includes the recent successful launch of Ibrance in the USA, make her a valued addition to our team as we endeavor to bring new therapeutic options to patients living with cancer.

“This is a very exciting time for our company as we advance our promising oncology and immuno-oncology pipeline and attract leading industry talent to Merck.”

29th April 2016

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...